Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species

American Journal of Tropical Medicine and Hygiene

Volumn 64, Issue 3-4, 2001, Pages 187-193

  Palacios, R ^a   Osorio, L E ^a   Grajales, L F ^a   Ochoa, M T ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; CHILD; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; EPITHELIZATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PARASITOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN LEISHMANIASIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034968735     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.64.187     Document Type: Article

References (32)

1. Estimation of population at risk of infection and number of cases of leishmaniasis
2. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
3. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam®) and review of pertinent clinical studies
4. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala
5. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years)
6. Successful treatment of New World cutaneous of topical paramomycin/methilbenzethonium chloride and injectable meglumine antimonate
7. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: Comparison of seven methods
8. Evaluation of Pentamidine for the treatment of cutaneous leishmaniasis in Colombia
9. Monoclonal antibodies that distinguish between New World species of Leishmania
10. Epidemiologic, genetic and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia
11. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis
12. Placebo controlled treatment of Ecuadorian cutaneous leishmaniasis
13. Placebo-controlled clinical trial of stibogluconate (Pentostam®) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala
14. Aminosidine (Paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis
15. Recurrent lesions in human Leishmania braziliensis infection-reactivation or reinfection?
16. Cutaneous scars in American tegumentary leishmaniasis patients: A site of Leishmania (Viannia) braziliensis and viability eleven years after antimonial therapy and clinical cure
17. Further evidence of humans as source of Leishmania Viannia for sandflies
18. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized controlled trial
19. Allopurinol in the treatment of American cutaneous leishmaniasis
20. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate
21. Epidemiology of cutaneous leishmaniasis in Colombia: Environmental and behavioral risk factors for infection, clinical manifestations, and pathogenicity
22. Drug resistance in leishmaniasis: Its implications in systemic chemotherapy of cutaneous and mucocutaneous disease
23. Sensitivity to Glucantime® of Leishmania Viannia isolated from patients prior to treatment
24. Sensitivity of Leishmania Viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes
25. Drug resistance in Leishmania: Similarities and differences to other organisms
26. Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection
27. Leishmania braziliensis from the Pacific Coast region of Colombia: Foci of transmission, clinical spectrum and isoenzyme phenotypes
28. Risk factors for onset of cutaneous and mucocutaneous leishmaniasis in Bolivia
29. The epidemiology of cutaneous leishmaniasis in subtropical Ecuador
30. Comparative study of American tegumentary leishmaniasis between childhood and teenagers from the endemic areas Buriticupu, Maranhão and Corte de Pedra, Bahía, Brazil